Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 0859-026 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will investigate the effect of MK0859 on lipoprotein metabolism in patients with dyslipidemia already on statin therapy.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Panel A | Experimental | Period 1: atorvastatin + placebo to MK0859; Period 2: atorvastatin + MK0859 |
|
| Panel B | Experimental | Period 1: placebo to atorvastatin + placebo to MK0859; Period 2: MK0859 + placebo to atorvastatin |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| anacetrapib | Drug | [Intervention Name: MK0859] MK0859 100 mg tablet once daily for 8 weeks. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Difference in Production Rate (PR) and Fractional Catabolic Rate (FCR) of Low Density Lipoprotein (LDL) apoB100 following treatment with MK0859 and atorvastatin versus atorvastatin alone | 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Difference in FCR of LDL apoB100 following treatment with MK0859 versus placebo | 12 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria :
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Monitor | Merck Sharp & Dohme LLC | Study Director |
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 25961461 | Background | Millar JS, Reyes-Soffer G, Jumes P, Dunbar RL, deGoma EM, Baer AL, Karmally W, Donovan DS, Rafeek H, Pollan L, Tohyama J, Johnson-Levonas AO, Wagner JA, Holleran S, Obunike J, Liu Y, Ramakrishnan R, Lassman ME, Gutstein DE, Ginsberg HN, Rader DJ. Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects. J Clin Invest. 2015 Jun;125(6):2510-22. doi: 10.1172/JCI80025. Epub 2015 May 11. | |
| 28729361 |
Not provided
Not provided
| ID | Term |
|---|---|
| D050171 | Dyslipidemias |
| ID | Term |
|---|---|
| D052439 | Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C530884 | anacetrapib |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Comparator: atorvastatin | Drug | Atorvastatin 20 mg tablet once daily for 4 weeks in Period 1 and 8 weeks in Period 2. |
|
| Comparator: placebo to MK0859 | Drug | Placebo to MK0859 once daily for 4 weeks. |
|
| Comparator: placebo to atorvastatin | Drug | Placebo to atorvastatin once daily for 4 weeks in Period 1 and 8 weeks in Period 2. |
|
| Derived |
| Thomas T, Zhou H, Karmally W, Ramakrishnan R, Holleran S, Liu Y, Jumes P, Wagner JA, Hubbard B, Previs SF, Roddy T, Johnson-Levonas AO, Gutstein DE, Marcovina SM, Rader DJ, Ginsberg HN, Millar JS, Reyes-Soffer G. CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects. Arterioscler Thromb Vasc Biol. 2017 Sep;37(9):1770-1775. doi: 10.1161/ATVBAHA.117.309549. Epub 2017 Jul 20. |